Foghorn Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit
Foghorn Therapeutics (Nasdaq: FHTX) announced management will present at the Guggenheim Emerging Outlook: Biotech Summit on February 11-12, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Foghorn Therapeutics (Nasdaq: FHTX) announced management will present at the Guggenheim Emerging Outlook: Biotech Summit on February 11-12, 2026. The company presentation is scheduled for Wednesday, February 11, 2026 at 3:00 p.m. EST by Adrian Gottschalk, President and CEO.
A live webcast will be available via the company’s Investors "Events & Presentations" page and will remain accessible for 30 days. Management will also conduct one-on-one meetings at the summit.
Details
News Market Reaction – FHTX
On Feb 3, the day this news came out, FHTX closed 2.74% below the previous close.
Data tracked by StockTitan Argus for the Feb 3 session.
Key Figures
- Summit dates
- February 11-12, 2026
- Guggenheim Emerging Outlook: Biotech Summit
- Presentation time
- 3:00 p.m. EST
- Company presentation on February 11, 2026
- Webcast availability
- 30 days
- Archived under Events & Presentations on company website
Historical Context
-
Closed $50M registered direct financing at a 30% premium.
-
Announced $50M equity financing and cash runway into first half 2028.
-
Participation in 8th Annual Evercore Healthcare Conference with webcast access.
-
Q3 2025 update with $180.3M cash and multiple degrader programs advancing.
-
Announcement of participation in three November 2025 investor conferences.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
WATERTOWN, Mass., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that management will participate in the Guggenheim Emerging Outlook: Biotech Summit, being held February 11-12, 2026, in New York, NY. With an initial focus in oncology, Foghorn’s Gene Traffic Control® platform and resulting broad pipeline have the potential to transform the lives of people suffering from a wide spectrum of diseases.
Presentation Date and Time: Wednesday February 11, 2026, at 3:00 p.m. EST
- Presenter: Adrian Gottschalk, President and Chief Executive Officer
- Please find a link to the webcast here
- Management will also participate in one-on-one meetings
A webcast of the presentation can be accessed under “Events & Presentations” in the Investors section of the Company’s website, www.foghorntx.com, and will be available for 30 days.
About Foghorn Therapeutics
Foghorn® Therapeutics is discovering and developing a novel class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Through its proprietary, scalable Gene Traffic Control® platform, Foghorn is systematically studying, identifying, and validating potential drug targets within the chromatin regulatory system. The Company is developing multiple product candidates in oncology. Visit our website at www.foghorntx.com for more information on the Company, and follow us on X and LinkedIn.
Contact:
Karin Hellsvik, Foghorn Therapeutics Inc. khellsvik@foghorntx.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.